122 related articles for article (PubMed ID: 25602245)
1. Advances in the treatment of tuberous sclerosis complex.
Leclezio L; de Vries PJ
Curr Opin Psychiatry; 2015 Mar; 28(2):113-20. PubMed ID: 25602245
[TBL] [Abstract][Full Text] [Related]
2. The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.
Cervi F; Saletti V; Turner K; Peron A; Bulgheroni S; Taddei M; La Briola F; Canevini MP; Vignoli A
Orphanet J Rare Dis; 2020 Sep; 15(1):237. PubMed ID: 32894194
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
4. Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey.
Waltereit R; Beaure d'Augères G; Jancic J; Kingswood JC; Koleva M; Marques R; Villanueva V; Auvin S
Orphanet J Rare Dis; 2021 May; 16(1):216. PubMed ID: 33980296
[TBL] [Abstract][Full Text] [Related]
5. International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).
de Vries PJ; Heunis TM; Vanclooster S; Chambers N; Bissell S; Byars AW; Flinn J; Gipson TT; van Eeghen AM; Waltereit R; Capal JK; Cukier S; Davis PE; Smith C; Kingswood JC; Schoeters E; Srivastava S; Takei M; Gardner-Lubbe S; Kumm AJ; Krueger DA; Sahin M; De Waele L; Jansen AC
J Neurodev Disord; 2023 Sep; 15(1):32. PubMed ID: 37710171
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Developmental and Behavioral Concerns in Toddlers With Tuberous Sclerosis Complex.
McDonald NM; Jacobs S; Hyde C; Kasari C; Jeste SS
Pediatr Neurol; 2024 Jun; 155():62-67. PubMed ID: 38603983
[TBL] [Abstract][Full Text] [Related]
7. Development and Feasibility of the Self-Report Quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ).
Heunis TM; Chambers N; Vanclooster S; Bissell S; Byars AW; Capal JK; Cukier S; Davis PE; de Vries MC; De Waele L; Flinn J; Gardner-Lubbe S; Gipson T; Kingswood JC; Krueger DA; Kumm AJ; Sahin M; Schoeters E; Smith C; Srivastava S; Takei M; van Eeghen AM; Waltereit R; Jansen AC; de Vries PJ
Pediatr Neurol; 2023 Oct; 147():101-123. PubMed ID: 37598571
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric comorbidities in tuberous sclerosis complex patients with epilepsy: results of the TAND checklist survey.
Lee HY; Lin CH; Wang XA; Tsai JD
Acta Neurol Belg; 2024 Jun; 124(3):973-979. PubMed ID: 38523222
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.
Cardis MA; DeKlotz CMC
Arch Dis Child; 2017 Sep; 102(9):858-863. PubMed ID: 28351834
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex.
de Vries PJ
Neurotherapeutics; 2010 Jul; 7(3):275-82. PubMed ID: 20643380
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex-associated neuropsychiatric disorders.
Marcinkowska AB; Tarasewicz A; Jóźwiak S; Dębska-Ślizień A; Szurowska E
Psychiatr Pol; 2022 May; ():1-20. PubMed ID: 36370437
[TBL] [Abstract][Full Text] [Related]
12. TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.
Kingswood JC; Bruzzi P; Curatolo P; de Vries PJ; Fladrowski C; Hertzberg C; Jansen AC; Jozwiak S; Nabbout R; Sauter M; Touraine R; O'Callaghan F; Zonnenberg B; Crippa S; Comis S; d'Augères GB; Belousova E; Carter T; Cottin V; Dahlin M; Ferreira JC; Macaya A; Benedik MP; Sander V; Youroukos S; Castellana R; Ulker B; Feucht M
Orphanet J Rare Dis; 2014 Nov; 9():182. PubMed ID: 25424195
[TBL] [Abstract][Full Text] [Related]
13. Seizure freedom but not epilepsy surgery is associated with fewer neuropsychiatric difficulties in patients with tuberous sclerosis.
Pearsson K; Eklund EA; Rask O; Compagno-Strandberg M
Epilepsy Behav; 2024 Jun; 157():109875. PubMed ID: 38824750
[TBL] [Abstract][Full Text] [Related]
14. Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
Curatolo P; Moavero R; de Vries PJ
Lancet Neurol; 2015 Jul; 14(7):733-45. PubMed ID: 26067126
[TBL] [Abstract][Full Text] [Related]
15. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.
Trelinska J; Dachowska I; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
Anticancer Drugs; 2015 Apr; 26(4):437-42. PubMed ID: 25719621
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex: multisystem hamartomas.
Naderi N; Timofte I; McCurdy MT; Reed RM
BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25618887
[No Abstract] [Full Text] [Related]
17. Tuberous sclerosis complex.
DiMario FJ; Sahin M; Ebrahimi-Fakhari D
Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
[TBL] [Abstract][Full Text] [Related]
18. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
Goyer I; Dahdah N; Major P
Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
[TBL] [Abstract][Full Text] [Related]
19. Tuberous Sclerosis Complex: An Update for Dermatologists.
Jacks SK; Witman PM
Pediatr Dermatol; 2015; 32(5):563-70. PubMed ID: 25776100
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
